Regor Therapeutics Group announced it will present results from its Phase 2a trial of RGT-075, an investigational oral GLP-1 receptor agonist, at the 85th Scientific Sessions of the American Diabetes Association taking place June 20-23 in Chicago. The presentation marks the first public disclosure of clinical data for the small molecule compound being developed for obesity and metabolic diseases.
Phase 2a Trial Results to Be Unveiled
The poster presentation, titled "First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity—A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study," is scheduled for Sunday, June 22, from 12:30 to 1:30 p.m. CDT at location 785P 12-B. The study evaluated RGT-075 in adults with obesity or overweight with weight-related comorbidities over a 12-week period.
Promising Early Clinical Profile
RGT-075 is an orally bioavailable, once-daily, small molecule GLP-1R full agonist discovered and developed by Regor for treating metabolic diseases, including type 2 diabetes mellitus and obesity or overweight with weight-related comorbidities. The Cambridge, Massachusetts-based company previously completed Phase 1 studies, including single ascending dose trials in healthy volunteers and multiple ascending dose studies in patients with diabetes.
According to Regor, RGT-075 demonstrated preliminary weight reduction in the study population during Phase 1 trials, with no new safety signals observed in completed studies. This early safety and efficacy profile supports the compound's advancement into larger Phase 2 trials.
Ongoing COMO-1 Phase 2b Development Program
RGT-075 is currently being evaluated in the COMO-1 dose-finding trial, a Phase 2b multicenter, randomized, double-blind, placebo-controlled study designed to evaluate multiple doses of RGT-075 over 36 weeks in adults with obesity or overweight with weight-related comorbidities. The trial has enrolled approximately 240 participants.
All participants receiving RGT-075 will be administered the drug once daily, with doses titrated up over 12 weeks. The primary endpoint is percent change in body weight from baseline to week 36. Secondary endpoints include safety and tolerability of the monthly titration scheme, as well as pharmacokinetics of RGT-075. Topline data from the Phase 2b study are expected at the end of 2025.
Strategic Focus on Metabolic Diseases
Regor Therapeutics Group operates as a clinical-stage biotechnology company with headquarters in Cambridge, Massachusetts, and additional operations in Houston, San Diego, and Shanghai. The company focuses on developing innovative and clinically differentiated medicines to address large unmet needs in oncology, metabolism, and auto-immunity.
The company's drug discovery efforts are powered by its rCARD (Regor Computer Accelerated Rational Discovery) platform, which enables rapid prototyping and validation of candidate molecules. This approach to developing small molecules against high-profile targets reflects the expertise of the company's four cofounders, who collectively brought decades of experience in leading US biopharma and were previously named inventors of four FDA-approved medicines.
The effectiveness of Regor's platform has been demonstrated through significant out-licensing deals, including a partnership with Roche/Genentech on next-generation CDK oncology agents RGT-419B and RGT-587 (now GDC-4198 and GDC-0587) for an $850 million upfront payment in late 2024, following an earlier endocrinology deal with a leading global biopharma company.
